| Name | Title | Contact Details |
|---|
Volpara Health Technologies Limited is a leading provider of breast imaging analytics and analysis products that improve clinical decision-making and the early detection of breast cancer. Every day, Volpara software helps clinicians better understand their patients and administrators better understand their practices. Volpara Health Technologies Limited (formerly Matakina Technology Limited) is a research, development, and manufacturing company based in Wellington, New Zealand. With a diverse research team led by internationally recognized experts in medical physics, as well as proprietary medical imaging technology covered by multiple patents and trademarks, we apply science to the solving of clinical problems around the world. Volpara Health Technologies Limited holds certification to ISO13485 and is a US FDA–registered establishment whose products are listed accordingly. In addition, our products hold CE Marking under European Medical Device Directive 93/42/EEC. Volpara Solutions Limited is our wholly owned sales and marketing subsidiary.
centennial medical group is a Ellicott City, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Medron International is a Mississauga, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Medikmark, Inc. was founded in 1987, and is now under the ownership of David H. Sanders. Medikmark is an FDA registered manufacturer maintaining a Class 100,000 clean room and 10,000 clean room and is a licensed drug wholesaler. Medikmark is also a small
Smith & Nephew is a global advanced medical technology business. We support healthcare professionals in more than 100 countries to improve the quality of life for their patients. Since 1856, when our founder T.J. Smith developed a new method for refining cod liver oil, and in World War One when his nephew led the supply of wound care products, to the present day, Smith & Nephew continues to pioneer health solutions. Through our market leadership positions in Sports Medicine, Trauma, Orthopaedic Reconstruction and Advanced Wound Management, our 16,000 employees continue to improve outcomes and expand access, constantly striving to create value for healthcare professionals, patients, payers and shareholders. Annual sales in 2016 were more than $4.6 billion. We are a constituent of the UK’s FTSE100 and our shares are traded on London Stock Exchange and through American Depository Receipts on the New York Stock Exchange We have leadership positions in Orthopaedic Reconstruction, Advanced Wound Management, Sports Medicine and Trauma. We have almost 11,000 employees and a presence in more than 90 countries. Annual sales in 2013 were more than $4.3 billion. We are a constituent of the UK's FTSE100 and our shares are traded on the London Stock Exchange and through American Depository Receipts on the New York Stock Exchange (LSE: SN, NYSE: SNN)